Európska únia - slovenčina - EMA (European Medicines Agency)

alfasigma s.p.a. - metyltioníniumchlorid - colorectal neoplasms; colonoscopy - other diagnostic agents - lumeblue is indicated as a diagnostic agent enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy.

Európska únia - slovenčina - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Európska únia - slovenčina - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vakcíny - profylaxia chrípky spôsobená vírusom a (h1n1) v roku 2009. celvapan by mali byť použité v súlade s oficiálne usmernenie.

Európska únia - slovenčina - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, tenofovir alafenamide - hiv infekcie - antivirotiká na systémové použitie - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

Európska únia - slovenčina - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leukémia, lymfocytárna, chronická, b-bunka - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

covidien iic 15 hampshire street ma 02048 mansfield, ma spojené štáty americké -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

nothern digital inc. 103 randall drive waterloo, ontario kanada -

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pelotherm, s.r.o., < & hviezdoslavova 4 900 25 chorvátsky grob slovensko -

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - eltrombopag - purpura, trombocytopenická, idiopatická - other systemic hemostatics, antihemorrhagics - revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (itp) who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 a 5. revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (itp) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e. corticosteroids, immunoglobulins) (see sections 4. 2 a 5. revolade is indicated in adult patients with chronic hepatitis c virus (hcv) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4. 4 and 5. revolade is indicated in adult patients with acquired severe aplastic anaemia (saa) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.

Európska únia - slovenčina - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anémia, kosáčiková bunka - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.